Ultrasound-targeted microbubble destruction optimized HGF-overexpressing bone marrow stem cells to repair fibrotic liver in rats.
Bone marrow mesenchymal stem cells
Hepatic growth factor
Liver fibrosis
Liver injury
Microbubble
Stem cell transplantation
Ultrasound
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
03 04 2020
03 04 2020
Historique:
received:
15
10
2019
accepted:
17
03
2020
revised:
11
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Bone marrow mesenchymal stem cells (BMSCs) have shown their therapeutic potential in cytotherapy for liver fibrosis. However, the insufficient homing of BMSCs and undefined proliferation of BMSCs represent a significant challenge and largely limit the effective implementation. The aims of the present study were to determine whether stable expression of hepatic growth factor (HGF) in BMSCs coupled with ultrasound-targeted microbubble destruction (UTMD) technique could effectively and definitely alleviating carbon tetrachloride (CCl4)-induced liver fibrosis in rats. A rat model of liver fibrosis was acquired by injection of carbon tetrachloride (CCl4). The experimental rats were randomly assigned to the four groups: normal, CCl4, BMSCs-HGF/US, and BMSCs-HGF/UTMD groups. The BMSCs, transfected by recombinant adeno-associated virus vector encoding human genome sequence of HGF (BMSCs-HGF), were transplanted in rat via the tail vein. The homing efficiency of BMSCs was observed by immunofluorescence staining. The liver function and its morphological changes were analyzed by biochemical tests and liver histology. The expression of liver fibrosis markers including α-smooth muscle actin (α-SMA), collagen I, and vimentin were examined by immunohistochemistry and quantitative real-time polymerase chain reaction. The homing efficiency of BMSCs in the fibrotic liver was significantly greater with the application of UTMD. The biochemical markers of liver function and histopathological results showed significantly better improvement in BMSCs-HGF/UTMD group than the other groups, and the serum levels of biochemical markers returned to normal ranges in 12 weeks in this group. Furthermore, the expression levels of liver fibrosis markers (α-SMA, collagen I, and Vimentin) were all significantly lower in BMSCs-HGF/UTMD group in comparison with other groups. Our findings have demonstrated that stable expression of HGF in BMSCs and application of the UTMD technique facilitate the homing of BMSCs, and more importantly, which could further improve their alleviation of liver fibrosis. Therefore, these findings have an important clinical implication that AAV-BMSCs-HGF and UTMD hold promise as a novel therapeutic approach for liver fibrosis.
Sections du résumé
BACKGROUND/AIMS
Bone marrow mesenchymal stem cells (BMSCs) have shown their therapeutic potential in cytotherapy for liver fibrosis. However, the insufficient homing of BMSCs and undefined proliferation of BMSCs represent a significant challenge and largely limit the effective implementation. The aims of the present study were to determine whether stable expression of hepatic growth factor (HGF) in BMSCs coupled with ultrasound-targeted microbubble destruction (UTMD) technique could effectively and definitely alleviating carbon tetrachloride (CCl4)-induced liver fibrosis in rats.
MATERIALS AND METHODS
A rat model of liver fibrosis was acquired by injection of carbon tetrachloride (CCl4). The experimental rats were randomly assigned to the four groups: normal, CCl4, BMSCs-HGF/US, and BMSCs-HGF/UTMD groups. The BMSCs, transfected by recombinant adeno-associated virus vector encoding human genome sequence of HGF (BMSCs-HGF), were transplanted in rat via the tail vein. The homing efficiency of BMSCs was observed by immunofluorescence staining. The liver function and its morphological changes were analyzed by biochemical tests and liver histology. The expression of liver fibrosis markers including α-smooth muscle actin (α-SMA), collagen I, and vimentin were examined by immunohistochemistry and quantitative real-time polymerase chain reaction.
RESULTS
The homing efficiency of BMSCs in the fibrotic liver was significantly greater with the application of UTMD. The biochemical markers of liver function and histopathological results showed significantly better improvement in BMSCs-HGF/UTMD group than the other groups, and the serum levels of biochemical markers returned to normal ranges in 12 weeks in this group. Furthermore, the expression levels of liver fibrosis markers (α-SMA, collagen I, and Vimentin) were all significantly lower in BMSCs-HGF/UTMD group in comparison with other groups.
CONCLUSIONS
Our findings have demonstrated that stable expression of HGF in BMSCs and application of the UTMD technique facilitate the homing of BMSCs, and more importantly, which could further improve their alleviation of liver fibrosis. Therefore, these findings have an important clinical implication that AAV-BMSCs-HGF and UTMD hold promise as a novel therapeutic approach for liver fibrosis.
Identifiants
pubmed: 32245503
doi: 10.1186/s13287-020-01655-1
pii: 10.1186/s13287-020-01655-1
pmc: PMC7119295
doi:
Substances chimiques
Hgf protein, rat
0
Intercellular Signaling Peptides and Proteins
0
Hepatocyte Growth Factor
67256-21-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Références
Cell Biol Int. 2014 Jan;38(1):106-16
pubmed: 24115681
Nature. 2015 Oct 15;526(7573):351-60
pubmed: 26469046
J Gastroenterol Hepatol. 2015 Jun;30(6):1065-74
pubmed: 25639333
Exp Biol Med (Maywood). 2009 Sep;234(9):1102-8
pubmed: 19546353
BMC Gastroenterol. 2014 Nov 25;14:198
pubmed: 25425284
Ther Deliv. 2012 Oct;3(10):1199-215
pubmed: 23116012
J Hepatol. 2017 Oct;67(4):770-779
pubmed: 28596109
Horm Metab Res. 2016 Nov;48(11):700-713
pubmed: 27871114
Adv Exp Med Biol. 2018;1103:243-253
pubmed: 30484233
Exp Mol Med. 2014 Aug 22;46:e110
pubmed: 25145391
BMC Complement Altern Med. 2015 Apr 11;15:115
pubmed: 25884170
Stem Cells. 2014 Nov;32(11):2818-23
pubmed: 25154380
Cell Tissue Res. 2013 Dec;354(3):717-28
pubmed: 24104560
Expert Rev Gastroenterol Hepatol. 2016;10(5):639-48
pubmed: 26691057
Mol Med Rep. 2013 Aug;8(2):320-6
pubmed: 23817930
J Biomater Sci Polym Ed. 2012;23(18):2259-72
pubmed: 22182291
Crit Rev Toxicol. 2003;33(2):105-36
pubmed: 12708612
J Nanobiotechnology. 2011 Apr 28;9:15
pubmed: 21526984
J Control Release. 2010 Oct 15;147(2):154-62
pubmed: 20493219
Exp Clin Transplant. 2018 Feb;16(1):81-89
pubmed: 28585911
Hepatol Res. 2015 Dec;45(13):1353-9
pubmed: 25692387
Clin Mol Hepatol. 2015 Jun;21(2):141-9
pubmed: 26157751
Stem Cells Int. 2015;2015:747245
pubmed: 25685159
Stem Cell Res Ther. 2018 Dec 29;9(1):356
pubmed: 30594241
Fibrogenesis Tissue Repair. 2013 Oct 01;6(1):19
pubmed: 24274743
Stem Cells Int. 2015;2015:691310
pubmed: 26074977
Sci Rep. 2016 Jan 22;6:19745
pubmed: 26797392
Mol Ther. 2018 Mar 7;26(3):845-859
pubmed: 29398486